Stock Research for SRNE


Featured Broker: Ally Invest

Get the due diligence for another stock.


SRNE Stock Chart & Research Data

The SRNE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SRNE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


SRNE Due diligence Resources & Stock Charts

The SRNE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SRNE Detailed Price Forecast - CNN Money CNN View SRNE Detailed Summary - Google Finance
Yahoo View SRNE Detailed Summary - Yahoo! Finance Zacks View SRNE Stock Research & Analysis -

Stock Analysis

TradeIdeas View SRNE Trends & Analysis - Trade-Ideas Barrons View SRNE Major Holders - Barrons
NASDAQ View SRNE Call Transcripts - NASDAQ Seeking View SRNE Breaking News & Analysis - Seeking Alpha
Spotlight View SRNE Annual Report - OTC Report View SRNE OTC Short Report -
TradeKing View SRNE Fundamentals - TradeKing Charts View SRNE SEC Filings - Bar Chart
WSJ View Historical Prices for SRNE - The WSJ Morningstar View Performance/Total Return for SRNE - Morningstar
MarketWatch View the Analyst Estimates for SRNE - MarketWatch CNBC View the Earnings History for SRNE - CNBC
StockMarketWatch View the SRNE Earnings - StockMarketWatch MacroAxis View SRNE Buy or Sell Recommendations - MacroAxis
Bullish View the SRNE Bullish Patterns - American Bulls Short Pains View SRNE Short Pain Metrics -

Social Media Mentions

StockTwits View SRNE Stock Mentions - StockTwits PennyStocks View SRNE Stock Mentions - PennyStockTweets
Twitter View SRNE Stock Mentions - Twitter Invest Hub View SRNE Investment Forum News - Investor Hub
Yahoo View SRNE Stock Mentions - Yahoo! Message Board Seeking Alpha View SRNE Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for SRNE - Insider Cow View Insider Transactions for SRNE - Insider Cow
CNBC View SRNE Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SRNE - OTC Markets
Yahoo View Insider Transactions for SRNE - Yahoo! Finance NASDAQ View Institutional Holdings for SRNE - NASDAQ

Stock Charts

FinViz View SRNE Stock Insight & Charts - StockCharts View SRNE Investment Charts -
BarChart View SRNE Stock Overview & Charts - BarChart Trading View View SRNE User Generated Charts - Trading View

Latest Financial News for SRNE

Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018
Posted on Wednesday September 19, 2018

Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia. Post-herpetic neuralgia (PHN), also referred to as post-shingles pain, is a frequent complication of shingles, a condition caused by the herpes zoster (HZ) virus, which afflicts an estimated 1 million people each year in the US.

Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication
Posted on Monday September 10, 2018

Sorrento Therapeutics, Inc. (SRNE) (“Sorrento”) announced today that its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), closed a debt financing with leading global institutional investors for aggregate gross proceeds to Scilex of $140 million. Scilex intends to use the net proceeds from this transaction for working capital and general corporate purposes in respect of commercialization of ZTlido™ (lidocaine topical system) 1.8%.  Morgan Stanley & Co. LLC acted as sole structuring agent for the transaction. “This non-dilutive financing provides Scilex with the capital resources to successfully execute on the launch of ZTlido,” said Henry Ji, Chairman, President and Chief Executive Officer of Sorrento and Scilex.

Scilex Presents ZTlido™ Data on Superior Adhesion over Lidocaine Patch Formulation
Posted on Friday September 07, 2018

- Data Presented at PAINWeek® Also Showed ZTlido Was Well-Tolerated and Demonstrated Bioequivalence to Lidoderm® Patch1,2 - Study Results Make Strong Case for ZTlido as Non-Opioid Treatment for Post-Shingles ...

Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Posted on Tuesday September 04, 2018

NEW YORK, Sept. 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

Stock Market & Investing Books

Enter a stock symbol to view the stock details.